Antibody-drug conjugates are a promising new option for gynecologic cancers, but they have a variety of ocular or vision-related adverse events that need to be appropriately monitored and managed.
While advances in immunotherapy have dramatically improved cancer survival, unleashing the immune system can lead to a host of adverse reactions. How can patients pay less of a price?